Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs
The efficacy of empagliflozin in managing T2DM and CVD is evaluated by this pooled analysis, highlighting great improvement in glycemic control and weight reduction. Further research is needed for empagliflozin's long-term safety and efficacy across populations.
Authors
- Satesh Kumar (ORCID: https://orcid.org/0009-0004-2215-311X)
- Laksh Kumar (ORCID: https://orcid.org/0009-0002-6978-5080)
- Salman M. Hyder (ORCID: https://orcid.org/0000-0002-4788-0127)
- Fathelrahman Mahdi Hassan (ORCID: https://orcid.org/0000-0002-2630-3208)
- Irfan Majeed
- Sunil Kumar (ORCID: https://orcid.org/0000-0002-9942-3403)
- Salih Abdella Yusuf
- Keziah Nithiya Suresh
- Dheeraj Kumar
- Deepika Deepika (ORCID: https://orcid.org/0000-0001-8345-1349)
- Vijay Kumar (ORCID: https://orcid.org/0000-0002-8649-5344)
- Kirti Batra
- Taimoor Ashraf
- Muskan Turesh
- Omar Abunada
- Fnu Kamlesh
Institutions
- Jinnah Postgraduate Medical Center (PK)
- Liaquat University of Medical & Health Sciences (PK)
- Nishtar Medical College and Hospital (PK)
- Hawassa University (ET)
- Liaquat National Hospital (PK)
- Shaheed Mohtarma Benazir Bhutto Medical University (PK)
- Dow University of Health Sciences (PK)
- Thumbay Group (United Arab Emirates) (AE)
- NIHR Surgical Reconstruction and Microbiology Research Centre (GB)
- Addis Ababa University (ET)
- Sukkur IBA University (PK)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1097/ms9.0000000000004512
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00